



**Department of Health and Human Services**  
Substance Abuse and Mental Health Services Administration  
Center for Substance Abuse Treatment

**Notice of Award**  
FAIN# H79TI085855  
**Federal Award Date**  
07/10/2026

**Recipient Information**

**1. Recipient Name**

COUNTY OF WEBB  
1110 WASHINGTON ST  
STE 101  
LAREDO, TX 78040

**2. Congressional District of Recipient**

28

**3. Payment System Identifier (ID)**

1746001587A5

**4. Employer Identification Number (EIN)**

746001587

**5. Data Universal Numbering System (DUNS)**

052767030

**6. Recipient's Unique Entity Identifier**

KJ57ZV6UCFB4

**7. Project Director or Principal Investigator**

Margarita Herrera-Garza

mhgarza@webbcountytx.gov  
956-523-4654

**8. Authorized Official**

Tano Tijerina  
cvaldez@webbcountytx.gov  
956-523-4000

**Federal Agency Information**

**9. Awarding Agency Contact Information**

Courtney Dodson  
Grants Specialist  
COURTNEY.DODSON@SAMHSA.HHS.GOV  
(240) 276-1849

**10. Program Official Contact Information**

Keji Ita  
Program Official  
keji.ita@samhsa.hhs.gov  
(240) 276-1294

**Federal Award Information**

**11. Award Number**

5H79TI085855-04

**12. Unique Federal Award Identification Number (FAIN)**

H79TI085855

**13. Statutory Authority**

Section 509 (42 USC 290bb-2) of the PHS Act, as amended

**14. Federal Award Project Title**

Webb County Adult Drug Court

**15. Assistance Listing Number**

93.243

**16. Assistance Listing Program Title**

Substance Abuse and Mental Health Services\_Projects of Regional and National Significance

**17. Award Action Type**

Non-Competing Continuation

**18. Is the Award R&D?**

No

**Summary Federal Award Financial Information**

**19. Budget Period Start Date 09/30/2026 – End Date 09/29/2027**

**20. Total Amount of Federal Funds Obligated by this Action** \$400,000

20a. Direct Cost Amount \$400,000

20b. Indirect Cost Amount \$0

21. Authorized Carryover

22. Offset

23. Total Amount of Federal Funds Obligated this budget period \$400,000

24. Total Approved Cost Sharing or Matching, where applicable \$0

25. Total Federal and Non-Federal Approved this Budget Period \$400,000

**26. Project Period Start Date 09/30/2023 – End Date 09/29/2028**

27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period \$1,600,000

**28. Authorized Treatment of Program Income**

Additional Costs

**29. Grants Management Officer - Signature**

LeSchell D Browne

**30. Remarks**

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.



SAMHSA Treatment Drug Courts  
Department of Health and Human Services  
Substance Abuse and Mental Health Services Administration

Notice of Award

**Issue Date:** 07/10/2026

Center for Substance Abuse Treatment

**Award Number:** 5H79TI085855-04  
**FAIN:** H79TI085855  
**Program Director:** Margarita Herrera-Garza

**Project Title:** Webb County Adult Drug Court

**Organization Name:** COUNTY OF WEBB

**Authorized Official:** Tano Tijerina

**Authorized Official e-mail address:** cvaldez@webbcountytx.gov

**Budget Period:** 09/30/2026 – 09/29/2027

**Project Period:** 09/30/2023 – 09/29/2028

Dear Grantee:

The Substance Abuse and Mental Health Services Administration hereby awards a grant in the amount of \$400,000 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to COUNTY OF WEBB in support of the above referenced project. This award is pursuant to the authority of Section 509 (42 USC 290bb-2) of the PHS Act, as amended and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Award recipients may access the SAMHSA website at [www.samhsa.gov](http://www.samhsa.gov) (click on "Grants" then SAMHSA Grants Management), which provides information relating to the Division of Payment Management System, HHS Division of Cost Allocation and Postaward Administration Requirements. Please use your grant number for reference.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

If you have any questions about this award, please contact your Grants Management Specialist and your Government Project Officer listed in your terms and conditions.

Sincerely yours,  
LeSchell D Browne  
Grants Management Officer  
Division of Grants Management  
[LeSchell.Browne@samhsa.hhs.gov](mailto:LeSchell.Browne@samhsa.hhs.gov)  
See additional information below

---

**SECTION I – AWARD DATA – 5H79TI085855-04****Award Calculation (U.S. Dollars)**

|                                                |               |
|------------------------------------------------|---------------|
| Personnel(non-research)                        | \$232,758     |
| Fringe Benefits                                | \$105,029     |
| Travel                                         | \$12,988      |
| Supplies                                       | \$1,110       |
| Contractual                                    | \$34,000      |
| Other                                          | \$14,115      |
| <br>Direct Cost                                | <br>\$400,000 |
| Approved Budget                                | \$400,000     |
| Federal Share                                  | \$400,000     |
| Cumulative Prior Awards for this Budget Period | \$0           |
| <br>AMOUNT OF THIS ACTION (FEDERAL SHARE)      | <br>\$400,000 |

| SUMMARY TOTALS FOR ALL YEARS |           |
|------------------------------|-----------|
| YR                           | AMOUNT    |
| 4                            | \$400,000 |
| 5                            | \$400,000 |

Note: Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

**Fiscal Information:**

CFDA Number: 93.243  
EIN: 1746001587A5  
Document Number: 23TI85855A  
Fiscal Year: 2026

|    |         |           |
|----|---------|-----------|
| IC | CAN     | Amount    |
| TI | C96N306 | \$400,000 |

|    |         |           |           |
|----|---------|-----------|-----------|
| IC | CAN     | 2026      | 2027      |
| TI | C96N306 | \$400,000 | \$400,000 |

**TI Administrative Data:**

PCC: DC-AD23 / OC: 4145

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5H79TI085855-04**

Payments under this award will be made available through the HHS Payment Management System (PMS). PMS is a centralized grants payment and cash management system, operated by the HHS Program Support Center (PSC), Division of Payment Management (DPM). Inquiries regarding payment should be directed to: The Division of Payment Management System, PO Box 6021, Rockville, MD 20852, Help Desk Support – Telephone Number: 1-877-614-5533.

The HHS Inspector General maintains a toll-free hotline for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. The telephone number is: 1-800-HHS-TIPS (1-800-447-8477). The mailing address is: Office of Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington, DC 20201.

---

**SECTION III – TERMS AND CONDITIONS – 5H79TI085855-04**

This award is based on the application submitted to, and as approved by, SAMHSA on the above-title project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. The restrictions on the expenditure of federal funds in appropriations acts to the extent those restrictions are pertinent to the award.
- c. 2 CFR 200 and 2 CFR 300 as applicable.
- d. The HHS Grants Policy Statement.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

**Treatment of Program Income:**

Use of program income – Additive: Recipients will add program income to funds committed to the project to further eligible project objectives. Sub-recipients that are for-profit commercial organizations under the same award must use the deductive alternative and reduce their subaward by the amount of program income earned.

---

**SECTION IV – TI SPECIAL TERMS AND CONDITIONS – 5H79TI085855-04****REMARKS****Federal Terms and Conditions for SAMHSA Grant Awards**

*This document outlines the federal terms and conditions applicable to your Substance Abuse and Mental Health Services Administration (SAMHSA) grant award. Please review these requirements carefully to ensure compliance throughout the life of the award.*

**Accepting the Award**

By drawing funds from the Department of Health and Human Services (HHS) Payment Management System (PMS), the recipient acknowledges acceptance of the award's terms and conditions and agrees to comply with all requirements.

HHS requires recipients to draw down funds within the first 30 days of the period of performance to indicate acceptance of the award. If the recipient fails to draw down funds or provide an acceptable written justification for the delay within this 30-day period, SAMHSA may take action to amend or withdraw the award offer.

Once an award is accepted by the recipient, the contents of this NoA are legally binding unless and until modified by a revised NoA signed by the Grants Management Officer (GMO).

**Declining or Negotiating the Award**

If the recipient cannot accept the award terms, the recipient's Authorized Organizational Representative (AOR) must notify the GMO in writing before drawing down any funds, and no later than thirty (30) days after receiving this NoA.

**Alignment with SAMHSA Mission and Strategic Priorities**

The recipient of this award must implement any funds awarded under this NOFO to advance program goals or agency priorities in alignment with the agency priorities at [SAMHSA's Strategic Priorities](#) when authorized by the program statute.

**Use of Supplies and Services for Harm Reduction Activities**

SAMHSA recipients are prohibited from using Federal funds, directly or indirectly, including through cost-sharing, matching funds, or subsequent reimbursement, to support so-called "harm reduction" or "safe consumption" efforts that facilitate illegal drug use.

Grant funds may not be used to purchase, distribute, or support drug paraphernalia as defined by law. This includes, but is not limited to, syringes or needles for illicit drug injection; pipes or supplies for safer smoking kits; fentanyl test strips or any other substance test kits, including xylazine and medetomidine

---

test strips\*; distribute any other drug paraphernalia or supplies that promote or facilitate drug use not listed here; purchase or distribute any other drug paraphernalia or supplies that promote or facilitate drug use not listed as acceptable in the [Dear Colleague Letter: Updated Funding Guidance for Grantees on Supplies and Services \(April 24, 2026\)](#). Funds also may not support overdose hotlines whose primary purpose is to enable drug use by providing real-time virtual or phone-based accompaniment.

These restrictions do not prohibit funding for legally permissible, evidence-based activities, such as the distribution of life-saving overdose prevention and response services, including purchase/distribution of naloxone or nalmefene and/or other infectious disease prevention services.

Failure to comply with the programmatic requirements in these letters: [Dear Colleague Letter: Executive Order on Ending Crime and Disorder on America's Streets America's Streets](#) and the [Dear Colleague Letter: Updated Funding Guidance for Grantees on Supplies and Services \(April 24, 2026\)](#) (which provides updated guidance for grantees on the supplies and services previously defined under harm reduction that can be supported with SAMHSA funding), may result in enforcement actions consistent with [2 CFR 200.339](#) and [2 CFR 200.340](#) and the terms and conditions of this award.

*\*This prohibition does not apply to law enforcement, emergency medical services, public health officials, or healthcare professionals using drug testing technologies in the regular course of discharging their professional duties, or as specifically authorized by the program statute.*

### **Appropriate Use of Funds for Medication-Assisted Treatment (MAT) / Medications for Opioid Use Disorder (MOUD)**

As referenced in the [Dear Colleague Letter: Updated Guidance on Medication-Assisted Treatment \(MAT\) and Medications for Opioid Use Disorder \(MOUD\)](#), SAMHSA funding should be used to provide comprehensive treatment and recovery support services rather than medication-only models for opioid use disorder. Services should include medications, where clinically indicated, in conjunction with psychosocial and other treatment and recovery support services. Funding can also be used to support individualized tapering and discontinuation of medications when clinically indicated.

Upon achieving stability in treatment and building sufficient recovery support, and at least annually, clinicians should engage in a discussion with patients to assess treatment and recovery goals and the continued use of medications. Continuation should be evaluated on an individual basis, taking into consideration progress toward treatment goals, stability in treatment, recovery capital, and patient preference.

When a shared decision to discontinue medication is made, discontinuation should be a gradual process with intensified support and monitoring to guard against resumption of drug use and done in the context of ongoing comprehensive care.

SAMHSA funding should be used to provide training to clinicians and other behavioral health providers on the clinically appropriate use of medications in the treatment of substance use disorders, including options for safe tapering and discontinuation when clinically indicated, and regular, at least annual, reviews for continuing treatment. This training should include strategies to support shared decision-making by ensuring patients are fully informed of the risks and benefits of medication treatment initiation, continuation, and discontinuation. Training must ensure providers educate patients about and facilitate access to comprehensive substance use treatment and recovery support services.

Training should include tools to support the development of individualized comprehensive treatment plans with patients that include consideration of medication treatment duration, and tapering and discontinuation, as clinically indicated based on the patient's individual circumstances, recovery, and preferences.

Failure to comply with the programmatic requirements found in: [Dear Colleague Letter: Updated Guidance on Medication-Assisted Treatment \(MAT\) and Medications for Opioid Use Disorder \(MOUD\)](#), may result in enforcement actions consistent with [2 CFR 200.339](#) and [2 CFR 200.340](#) and the terms and conditions of this award.

### **Antidiscrimination Compliance Requirement**

By applying for or accepting federal funds from HHS, recipients certify compliance with all federal antidiscrimination laws and these requirements and that complying with those laws is a material condition of receiving federal funding streams. Recipients are responsible for ensuring subrecipients, contractors,

---

and partners also comply.

#### **Civil Rights Compliance Requirement**

The Applicant hereby agrees that it will comply with Title VI of the Civil Rights Act of 1964, as amended (codified at 42 USC 2000d et seq.), and all requirements imposed by or pursuant to the Regulation of the Department of Health and Human Services (45 CFR Part 80); Section 504 of the Rehabilitation Act of 1973, as amended (codified at 29 USC 794), and all requirements imposed by or pursuant to the Regulation of the Department of Health and Human Services (45 CFR Part 84); Title IX of the Education Amendments of 1972, as amended (codified at 20 USC 1681 et seq.), and all requirements imposed by or pursuant to the Regulation of the Department of Health and Human Services (45 CFR Part 86); The Age Discrimination Act of 1975, as amended (codified at 42 USC 6101 et seq.), and all requirements imposed by or pursuant to the Regulation of the Department of Health and Human Services (45 CFR Part 91); and Section 1557 of the Patient Protection and Affordable Care Act, as amended (codified at 42 USC 18116), and all requirements imposed by or pursuant to the Regulation of the Department of Health and Human Services (45 CFR Part 92).

#### **Title IX Compliance Requirement**

By accepting this award, including the obligation, expenditure, or drawdown of award funds, recipient certifies as follows:

- Recipient is compliant with Title IX of the Education Amendments of 1972, as amended, 20 USC 1681 et seq., including the requirements set forth in Presidential Executive Order 14168 titled Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government, and Title VI of the Civil Rights Act of 1964, 42 USC 2000d et seq., and Recipient will remain compliant for the duration of the Agreement.
- The above requirements are conditions of payment that go to the essence of the Agreement and are therefore material terms of the Agreement.
- Payments under the Agreement are predicated on compliance with the above requirements, and therefore Recipient is not eligible for funding under the Agreement or to retain any funding under the Agreement absent compliance with the above requirements.
- Recipient acknowledges that this certification reflects a change in the government's position regarding the materiality of the foregoing requirements and therefore any prior payment of similar claims does not reflect the materiality of the foregoing requirements to this Agreement.
- Recipient acknowledges that a knowing false statement relating to Recipient's compliance with the above requirements and/or eligibility for the Agreement may subject Recipient to liability under the False Claims Act, 31 USC 3729, and/or criminal liability, including under 18 USC 287 and 1001.

#### **Compliance with Court Orders**

Any term or condition in this NoA, including those incorporated by reference, that HHS is enjoined by court order from imposing or enforcing shall not apply or be enforced as to any recipient or subrecipient to which that court order applies and while that court order is in effect.

#### **Termination**

This award is subject to the termination provisions at 2 CFR 200.340. Pursuant to 2 CFR 200.340, the recipient agrees by accepting this award that continued funding for the award is contingent upon the availability of appropriated funds, recipient satisfactory performance, compliance with the Terms and Conditions of the award, and may also otherwise be terminated, to the extent authorized by law, if the agency determines that the award no longer effectuates program goals or agency priorities.

## **1. Budget and Funding Overview**

### **Award Approval**

- This Notice of Award (NoA) approves the budget submitted on [[Month Day, Year]].

### **Budget Period Compliance**

- 
- Recipients must ensure that funds are spent within the 12-month budget period specified in the Notice of Award (NoA) according to the approved budget.

## 2. Regulatory Requirements

This award is subject to any applicable provisions of 2 CFR 200 and 2 CFR 300.

## 3. Key Personnel

### Effort Limitations

- Total effort across all funding sources (federal and non-federal) for any individual may not exceed 100% level of effort.

### Definition of Key Personnel

- Key Personnel are essential staff or consultants/subrecipients who must be part of the project regardless of whether they receive a salary or compensation from the project.

### Designated Key Personnel

- For this program, the following role(s) are designated as Key Personnel:
  - o Project Director (PD)
  - o [[add additional bullets/position title(s) if needed according to the NOFO e.g., Evaluator, Case Manager, etc.]]
- The identified PD for this program is listed in item #7 Project Director or Principal Investigator on the cover page of the NoA. If the individual identified on the NoA is incorrect, you must submit a post-award amendment for a change in Key Personnel via eRA Commons.

### Key Personnel Changes Requiring Approval

Any changes to Key Personnel, including:

- The proposal of new staff in a Key Personnel role, or
- A separation from the project for three months or longer, or
- A reduction in effort of 25% or more

**Note:** Hiring Key Personnel before receiving formal approval is at the recipient's own risk.

## 4. Reporting Requirements

*All reports must be submitted by the deadlines outlined below. Late submissions may result in additional consequences, including denial of future funding or unilateral project closeout.*

### A. Federal Financial Report (FFR/SF-425)

- **Due: By December 28, 2027**
- **Submission Method:** Via the Payment Management System (PMS)
- **Requirements:**
  - o Recipients must request appropriate PMS user access
  - o Reports sent by email or uploaded to eRA Commons will not be accepted
  - o See [Instructions for FFR Submission](#) (must be logged in to PMS to access)

### B. Programmatic Progress Report (PPR)

- **Due: Annual Progress Report due December 29, 2027**

- 
- **Semi-Annual Progress Report due April 30, 2027**
  - **Submission Method:** Via eRA Commons
  - **Content Must Include:**
    - o Performance measures data and evaluation results
    - o Summary of key accomplishments
    - o Description of changes made during the budget period
    - o Challenges encountered and actions taken to address them

### **C. Final Reports (for Closeout)**

- **Due:** Within 120 days after the project period ends
- **Required Reports:**
  - o Final Federal Financial Report (Final FFR/SF-425) via PMS
  - o Final Progress Report (FPR) via eRA Commons
  - o Tangible Personal Property Report (Final TPPR Report SF-428-B and SF-428-S, as applicable) via eRA Commons
- **Consequences for Failure to Submit Acceptable Final Reports:**
  - o Unilateral closeout by SAMHSA
  - o Reporting recipient's material failure to comply with the terms and conditions of the Federal award in SAM.gov (Responsibility/Qualification Records)
  - o Impact on eligibility for future federal funding or other enforcement actions as appropriate (refer to [2 CFR 200.339](#))
- **Closeout Liquidation Period:**
  - o All obligations must be liquidated no later than 120 days after the project period end date
  - o After one hundred twenty (120) days, the PMS account is automatically locked. SAMHSA does not approve payment requests after the one hundred twenty (120) day liquidation of obligations period; late drawdown requests occurring after the 120 days will be denied.
- Additional closeout information and instructions on submitting reports are available at [SAMHSA Grant Closeout](#)

## **5. Government Performance and Results Act (GPRA) Compliance**

### **Data Collection and Performance Measurement**

All SAMHSA recipients are required to collect and report evaluation data to ensure the effectiveness and efficiency of its programs under the Government Performance and Results (GPRA) Modernization Act of 2010 (P.L. 111-352). Recipients must comply with the performance goals, milestones, and expected outcomes as reflected in the NOFO and are required to submit data via SAMHSA's Performance Accountability and Reporting System (SPARS).

SAMHSA's performance measurement tools have been updated to comply with Presidential Executive Orders.

## **6. Financial Management Standards**

Recipients must maintain financial systems that:

- Track sources and uses of federal funds
- Compare actual expenditures to approved budgets
- Keep federal funds separate from other funds (no commingling)
- Ensure that all costs charged to awards are:
  - o Allowable
  - o Allocable
  - o Reasonable
  - o Necessary
  - o Consistently applied in accordance with **2 CFR 200** and **2 CFR 300** as applicable

---

## 7. Consequences for Noncompliance

Failure to comply with terms and conditions may result in:

- Withholding of payments
- Disallowance of costs
- Suspension or termination of the award
- Denial of future funding

Remedies for noncompliance are governed by [2 CFR 200.339](#).

## 8. Post Award Amendments and Responses

All responses to award terms and post award amendment requests must be submitted in eRA Commons. For instructions, see [SAMHSA Post Award Amendments](#).

## 9. Standard Terms and Conditions

Recipients must comply with:

- The [HHS Grants Policy Statement](#) (current version)
- [2 CFR 200](#) and [2 CFR 300](#)
- [SAMHSA Standard Terms and Conditions](#) in effect at the time of award

All prior terms and conditions remain in effect unless formally revised or removed by the Grants Management Officer.

### Staff Contacts:

Keji Ita, Program Official  
**Phone:** (240) 276-1294 **Email:** keji.ita@samhsa.hhs.gov

Courtney Dodson, Grants Specialist  
**Phone:** (240) 276-1849 **Email:** COURTNEY.DODSON@SAMHSA.HHS.GOV